Arvinas Inc jobs

Senior Research Scientist - Neuroscience New Haven - CT Arvinas is a biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer PROteolysis TArgeting Chimeras, or PROTACs, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. This differentiated approach has enabled Arvinas to build a broad pipeline of investigational therapies across oncology and neurodegenerative diseases, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal bulbar muscular atrophy; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Building on its leadership in targeted protein degradation, Arvinas achieved a major milestone in May 2026 with the first-ever U.S. Food and Drug Administration (FDA) approval of a PROTAC protein degrader therapy. The approval marked a significant advancement for the field and demonstrated the therapeutic potential of targeted protein degradation as a novel treatment modality. This PROTAC has been out-licensed for commercialization and further development. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back.

Early Development Team Leader Remote, Hybrid, New Haven - CT Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. On August 8 th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical

DMPK Scientist Remote, Hybrid, New Haven - CT Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. On August 8 th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the

Senior Medical Director Clinical Development Neuroscience Remote, Hybrid, New Haven - CT Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. On August 8 th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development

Vice President, Technical Operations Remote, Hybrid, New Haven - CT Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. On August 8 th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization

ServiceNow Architect Warsaw, Masovian Voivodeship, Poland Company Description: Arηs Group, Part of Accenture, specializes in the management of complex public sector IT projects, including systems integration, informatics and analytics, solution implementation and program management. Our team helps lead clients through digital and information systems design, bringing expertise in a variety of areas ranging from software development, data science and security management to machine learning, cloud, and mobile development. Arηs Group was acquired by Accenture in July 2024. Job Description: ServiceNow Architecture & Design Define and maintain ServiceNow platform architecture Set standards for design, development, quality, and testing Design integrations and interoperability with external systems Translate business needs into architecture models and roadmaps Evaluate and select appropriate technologies Optimise platform performance, security, and quality Business Analysis Gather and assess business and user requirements Translate requirements into technical solutions Ensure alignment between business needs and architecture design Present solutions to technical and non-technical stakeholders Platform Governance & Delivery Supervise ServiceNow implementations and improvements Support development teams and architects in solution design Ensure consistency in service management capabilities Continuous Improvement & Documentation Recommend improvements to architecture and processes Support risk, security, and continuity planning Maintain technical documentation, SOPs, and knowledge base articles Analyse system metrics and drive improvements Qualifications: Strong hands-on experience with ServiceNow platform architecture and design Solid understanding of ServiceNow products and service management concepts Experience with ServiceNow administration and maintenance Integration & architecture: REST APIs, Web Services Single Sign-On (SSO), LDAP Complex system integrations and interoperability Modelling & documentation: Enterprise

AR Collector with Italian AR Collector with Italian Infosys Poland Sp. z o.o. - Łódź We are looking for a candidate with: 1 year of collection experience preferably Italian and English at least at level B2 (as per client's communication purposes) Attention to detail with a clear focus on cash collection Ability to independently prioritize and manage own workload Excel skills, including reading and preparing reports Your key activities: Follow up with clients on outstanding invoices Ensure the accounts receivable ledger is accurate and up to date Monitor and control ageing buckets Customer orientation and proactive approach You can expect from us: Performance bonus twice a year Employee referral program bonus Opportunity for professional growth through internal movement (horizontal or vertical) and internal trainings online/onsite Access to training platform (self-learning), domain/soft/technical skills training Possibility to use Italian language on a daily basis Private medical care at Medicover (with possible extension to family members) Reimbursement of Multisport card or points on MyBenefit platform Attractive group insurance Access to well-being platform, free meetings with a psychologist included Stable employment based on an employment contract No trial period IT equipment is provided by the Company Bonuses from the Social Fund Flexible starting hours Opportunity to participate in charity, sports and well-being events Hybrid mode (2 work days from the office per week) Recruitment stages: CV check -> Call with the Recruiter -> Skills check (online test(s) and phone language verification - if required) -> Video meeting with Hiring Manager -> Final decision and

AR Specialist with Spanish - Lodz AR Specialist with Spanish - Lodz Infosys Poland Sp. z o.o. - Łódź - hybrid 2/3 We are looking for a candidate with: Experience in customer-facing roles Spanish (C1/C2), English C1 (essential for client's communication purposes) Min 2 years of experience in working with clients (in AR domain) Good communication skills, attitude for problem solving and teamwork skills Good knowledge of MS Office package Highly developed, self-organization Your key activities: Telephone contact in Italian (responding to phone calls, e-mails, and queries from the clients) Perform cash collection activities - chasing customers, managing open items Performing Cash Application, Order Release and Credit Limit review activities Managing Customer Refunds Supporting AR team with payment methods maintaining Preparing daily, weekly, and monthly regular financial reports Ongoing e-mail communication in Italian and English Collaborating with other teams and internal customers You can expect from us: Performance bonus twice a year Employee referral program bonus Opportunity for professional growth through internal movement (horizontal or vertical) and internal trainings online/onsite Access to training platform (self-learning), domain/soft/technical skills training Possibility to use English and Spanish languages on a daily basis Private medical care at Medicover (with possible extension to family members) Reimbursement of Multisport card or points on MyBenefit platform Attractive group insurance Access to well-being platform, free meetings with a psychologist included Stable employment based on an employment contract No trial period IT equipment is provided by the Company Bonuses from the Social Fund Flexible starting hours Opportunity to participate

AR Specialist with Italian - Lodz AR Specialist with Italian - Lodz Infosys Poland Sp. z o.o. - Łódź - hybrid 2/3 We are looking for a candidate with: Experience in customer-facing roles Italian (C1/C2), English C1 (essential for client's communication purposes) Min 2 years of experience in working with clients (in AR domain) Good communication skills, attitude for problem solving and teamwork skills Good knowledge of MS Office package Highly developed, self-organization Your key activities: Telephone contact in Italian (responding to phone calls, e-mails, and queries from the clients) Perform cash collection activities - chasing customers, managing open items Performing Cash Application, Order Release and Credit Limit review activities Managing Customer Refunds Supporting AR team with payment methods maintaining Preparing daily, weekly, and monthly regular financial reports Ongoing e-mail communication in Italian and English Collaborating with other teams and internal customers You can expect from us: Performance bonus twice a year Employee referral program bonus Opportunity for professional growth through internal movement (horizontal or vertical) and internal trainings online/onsite Access to training platform (self-learning), domain/soft/technical skills training Possibility to use English and Italian languages on a daily basis Private medical care at Medicover (with possible extension to family members) Reimbursement of Multisport card or points on MyBenefit platform Attractive group insurance Access to well-being platform, free meetings with a psychologist included Stable employment based on an employment contract No trial period IT equipment is provided by the Company Bonuses from the Social Fund Flexible starting hours Opportunity to participate

Marketing Sales,Influencer Marketing - MIHA, Inc. (A&M) Tokyo, Japan posted: Posted 4 Days Ago

Sales planning - MIHA, Inc. (A&M) Tokyo, Japan posted: Posted 30+ Days Ago

PalletOne Inc. Assembly Department Hazlehurst, GA (PalletOne) posted:

PalletOne Inc. Cutting Department Hazlehurst, GA (PalletOne) posted:

Cloud Engineer - Rakuten Wallet, Inc. Tokyo, Japan posted: Posted 30+ Days Ago

Chief Compliance Officer (CCO) for Truist Investment Services, Inc. and Truist Advisory Services, Inc. 3 Locations posted: Posted 14 Days Ago

Project Manager - Rakuten Wallet, Inc. Tokyo, Japan posted: Posted 30+ Days Ago

PalletOne Inc. Electrical Maintenance Tech Bartow, FL (529) posted:

PalletOne Inc. Pallet Assembler I Bartow, FL (529) posted:

AVS Saltillo, Coahuila, Mexico HSBC México, ofrecemos oportunidades para desarrollar una carrera profesional para personas con excelente actitud de servicio, trato al cliente, gusto por las ventas y visión por desarrollarse en el área Comercial en el puesto de Ejecutivo de Servicio. Función principal. Mejorar la experiencia del cliente en Sucursal a través de su atención en ventanilla y de acuerdo a las necesidades de la sucursal. Promoviendo a clientes actuales y potenciales nuestros productos y servicios referenciándolos a

Engineering Manager - Rakuten Wallet, Inc. Tokyo, Japan posted: Posted 30+ Days Ago

Data Scientist - Frontend System Development Department, Rakuten Payment, Inc. Tokyo, Japan posted: Posted 4 Days Ago

PalletOne Inc. Forklift Operator Bartow, FL (529) posted:

Producer - Point Card System Development Department, Rakuten Payment, Inc. Tokyo, Japan posted: Posted 30+ Days Ago

Consultant - Oracle Cloud Inventory Consultant About Infosys : Infosys is a global leader in next-generation digital services and consulting. We enable clients in 56 countries to navigate their digital transformation. With over three decades of experience in managing the systems and workings of global enterprises, we expertly steer our clients through their digital journey. We do it by enabling the enterprise with an AI-powered core that helps prioritize the execution of change. We also empower the business with agile digital at scale to deliver unprecedented levels of performance and customer delight. Our always-on learning agenda drives their continuous improvement through building and transferring digital skills, expertise, and ideas from our innovation ecosystem. Visit www.infosys.com to see how Infosys (NYSE: INFY) can help your enterprise navigate your next. Infosys has been recognized as a Top Employer across APAC - contributing to our sixth consecutive year of global certification. As an AI‑first organization, we empower our people to work on next‑generation technologies, continuously learn, and create impact at scale-supported by a culture rooted in care, inclusion, and excellence. ▶️Join Infosys and be part of a culture that's not just promised-it's certified. #TopEmployer2026 #ThriveAtInfosys Role: Functional - Oracle Inventory Management Cloud Consultant Location: Tokyo Based on your role, please note that this position may require on-site presence at Infosys premises and/or client locations. Work location and on-site expectations will depend on project scope, phase, and business needs at the time of allocation, with flexibility governed by business and client requirements Skills: -